Medtronic warning letter
This article was originally published in The Gray Sheet
Executive Summary
Firm's Synchromed II and MiniMed Paradigm insulin pumps are subject to a June 1 FDA warning letter. During a Nov. 12-Dec. 15, 2008, inspection of Medtronic's Puerto Rico manufacturing facility, FDA identified quality system violations related to manufacture of the Synchromed devices and medical device reporting violations related to the Paradigm pumps. For example, Synchromed pumps were distributed and implanted in patients without being filled with a necessary propellant, but the firm took nearly two years to conduct a recall. In addition, Medtronic failed to report device-related serious injuries to FDA in a timely manner, the agency charges
You may also be interested in...
Medtronic responds to warning letter
The firm is preparing a response to a recent FDA warning letter relating to an August inspection of its Cardiac Rhythm Disease Management facility in Mounds View, Minn. Medtronic says it has "already begun to implement changes and put procedures in place related to each of the observations cited during the inspection, and any additional actions that may be required will be put in place as quickly as possible." The letter notes deficiencies in corrective and preventive action and field action timeliness; review and documentation of field action recommendations; supplier qualification and controls; and medical device reporting timeliness. According to Medtronic, FDA's letter acknowledges that the firm's promised corrective actions appear adequate to address the agency's observations. The firm previously received a warning letter in June addressed to its Juncos, Puerto Rico, facility related to quality system regulation and medical device reporting issues (1"The Gray Sheet" June 29, 2009)
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.